HC Andersen Capital: Qlife sector update
Qlife peer LumiraDX released the first survey among clinicians in the UK for POCT (Point of Care Testing) beginning of December 2022. The survey is single blinded and aims to measure the clinician’s perception of POCT pros and cons.This is very interesting news, because Qlife launch their first ”assay” addressing the CRP market in Europe in the first quarter of 2023. This ”assay” will be launched under the Egoo Health brand.Feedback from the survey, supports the 3 major trends within the POCT-market. Main conclusions · PATIENT CARE: Clinicians ranked ‘Improved quality of care’